Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
SELECT Proves Semaglutide 2.4 mg CV Benefit at AHA 2023
In this episode, hosts take a deep dive into the study’s results, including secondary endpoints, and what it means for the care of patients with overweight or obesity and preexisting cardiovascular disease in real-world settings.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.